Yogev Yariv, Langer Oded, Xenakis Elly M J, Rosenn Barak
Department of Obstetrics and Gynecology, St. Luke's-Roosevelt Hospital Center, University Hospital of Columbia University, 1000 Tenth Avenue, Suite 11A, New York, NY 10019, USA.
Obstet Gynecol. 2004 Jun;103(6):1241-5. doi: 10.1097/01.AOG.0000124781.98059.fe.
We sought to describe the predictive value for gestational diabetes mellitus (GDM) using different glucose challenge test thresholds in Mexican-American women.
A prospective population-based study of 6,857 gravid women, who were tested with a 50-g glucose challenge test at 24-28 weeks of gestation, was performed. A screening value of 130 mg/dL or greater was followed by a 3-hour, 100-g oral glucose tolerance test. Gestational diabetes mellitus was diagnosed by 2 or more abnormal values using the Carpenter and Coustan criteria. For purpose of analysis, GDM diagnosis was categorized with glucose challenge test values in 10-mg/dL increments. A comparison between Carpenter-Coustan and the National Diabetic Data Group criteria for GDM diagnosis was performed for each glucose challenge test threshold category. Sensitivity and specificity for GDM diagnosis were further calculated for different glucose challenge test thresholds (130, 135, and 140 mg/dL).
Overall, GDM was diagnosed in 469 of 6,857 (6.8%) women, and one abnormal oral glucose tolerance test value was tested in 351 of 6,857 women (5.1%). Normal glucose challenge test results (threshold less than 130 mg/dL) were obtained in 4,316 of 6,857 women. An elevated glucose challenge test value increases the risk of GDM, but even in high glucose challenge test thresholds (more than 180 mg/dL), the predictive value for GDM was only 50%. The sensitivity and specificity for GDM diagnosis using 3 different glucose challenge test thresholds were as follows: threshold 130 mg/dL or more: 97% and 63%; threshold 135 mg/dL or more: 91% and 73%; and threshold 140 mg/dL or more: 85% and 78%, respectively.
Data suggests that an elevated glucose challenge test level cannot be used as a single diagnostic tool for GDM even in high test thresholds. A threshold of 130 mg/dL may be recommended as a screening threshold for GDM in Mexican-American women.
II-3
我们试图描述不同葡萄糖耐量试验阈值对墨西哥裔美国女性妊娠糖尿病(GDM)的预测价值。
对6857名孕妇进行了一项基于人群的前瞻性研究,这些孕妇在妊娠24至28周时接受了50克葡萄糖耐量试验。筛查值为130mg/dL或更高时,随后进行3小时、100克口服葡萄糖耐量试验。根据Carpenter和Coustan标准,2个或更多异常值可诊断为妊娠糖尿病。为了分析,将GDM诊断按照葡萄糖耐量试验值以10mg/dL的增量进行分类。对每个葡萄糖耐量试验阈值类别进行了Carpenter-Coustan标准与国家糖尿病数据组GDM诊断标准之间的比较。还针对不同的葡萄糖耐量试验阈值(130、135和140mg/dL)进一步计算了GDM诊断的敏感性和特异性。
总体而言,6857名女性中有469名(6.8%)被诊断为GDM,6857名女性中有351名(5.1%)口服葡萄糖耐量试验有一个异常值。6857名女性中有4316名葡萄糖耐量试验结果正常(阈值低于130mg/dL)。葡萄糖耐量试验值升高会增加患GDM的风险,但即使在高葡萄糖耐量试验阈值(超过180mg/dL)下,GDM的预测价值也仅为50%。使用3种不同葡萄糖耐量试验阈值诊断GDM的敏感性和特异性如下:阈值130mg/dL或更高:97%和63%;阈值135mg/dL或更高:91%和73%;阈值140mg/dL或更高:分别为85%和78%。
数据表明,即使在高试验阈值下,葡萄糖耐量试验水平升高也不能用作GDM的单一诊断工具。对于墨西哥裔美国女性,建议将130mg/dL的阈值作为GDM的筛查阈值。
II-3